Current Urology (Dec 2021)

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor

  • Jun Teishima,
  • Daiki Murata,
  • Shogo Inoue,
  • Tetsutaro Hayashi,
  • Koji Mita,
  • Yasuhisa Hasegawa,
  • Masao Kato,
  • Mitsuru Kajiwara,
  • Masanobu Shigeta,
  • Satoshi Maruyama,
  • Hiroyuki Moriyama,
  • Seiji Fujiwara,
  • Akio Matsubara

DOI
https://doi.org/10.1097/CU9.0000000000000042
Journal volume & issue
Vol. 15, no. 4
pp. 187 – 192

Abstract

Read online

Abstract. Background:. There are various alternative first-line therapeutic options besides tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). To inform therapeutic decision-making for such patients, this study aimed to identify predictive factors for resistance to TKI. Materials and methods:. A total of 239 cases of mRCC patients who received first-line TKI therapy were retrospectively studied. Patients with a radiologic diagnosis of progressive disease within 3 months after initiating therapy were classified as primary refractory cases; the others were classified as non-primary refractory cases. The association between primary refractory cases and age, gender, pathology findings, serum c-reactive protein (CRP) level, metastatic organ status, and 6 parameters defined by the International Metastatic Renal Cell Carcinoma Database Consortium were analyzed. Results:. Of 239 cases, 32 (13.3%) received a radiologic diagnosis of progressive disease within 3 months after initiating therapy. The rates of sarcomatoid differentiation, hypercalcemia, a serum CRP level of 0.3 mg/dL or higher, presence of liver metastasis, anemia, and time from diagnosis to treatment interval of less than a year were significantly higher in the primary refractory group. Multivariate analysis showed that sarcomatoid differentiation, hypercalcemia, a serum CRP level of 0.3 mg/dL or higher, and liver metastasis were independently associated with primary refractory disease. A risk-stratified model based upon the number of patients with these factors indicated rates of primary refractory disease of 4.0%, 10.1%, and 45.0% for patients with 0, 1, and 2 or more factors, respectively. Conclusions:. Sarcomatoid differentiation, hypercalcemia, an elevated serum CRP level, and presence of liver metastasis were associated with primary refractory disease in mRCC patients receiving first-line TKI therapy. These results provide clinicians with useful information when selecting a first-line therapeutic option for mRCC patients.